Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE

Original Publication: Oxford : Wiley-Blackwell

Tenecteplase*/therapeutic use ; Fibrinolytic Agents*/therapeutic use ; Ischemic Stroke*/drug therapy ; Thrombolytic Therapy*/methods ; Tissue Plasminogen Activator*/therapeutic use ; Tissue Plasminogen Activator*/administration & dosage ; Tissue Plasminogen Activator*/adverse effects; Humans ; Treatment Outcome ; Animals

Although intravenous thrombolysis with alteplase remains the primary treatment for acute ischemic stroke, tenecteplase has shown potential advantages over alteplase. Animal studies have demonstrated the favorable pharmacokinetics and pharmacodynamics of tenecteplase. Moreover, it is easier to administer. Clinical trials have demonstrated that tenecteplase is not inferior to alteplase and may even be superior in cases of acute ischemic stroke with large vessel occlusion. Current evidence supports the time and cost benefits of tenecteplase, suggesting that it could potentially replace alteplase as the main option for thrombolytic therapy, especially in patients with large vessel occlusion.

Hamostaseologie. 2015;35(4):303-10. (PMID: 25564072)
Lancet. 2007 Jan 27;369(9558):275-82. (PMID: 17258667)
N Engl J Med. 1965 Oct 28;273(18):966-73 contd. (PMID: 5319085)
Stroke. 2020 May;51(5):1530-1538. (PMID: 32248771)
J Pers Med. 2022 Sep 17;12(9):. (PMID: 36143310)
Lancet Neurol. 2022 Jun;21(6):511-519. (PMID: 35525250)
Stroke. 1994 Oct;25(10):2072-8; discussion 2078-9. (PMID: 8091454)
Lancet. 2022 Jul 16;400(10347):138-139. (PMID: 35779556)
Stroke. 2020 Nov;51(11):3440-3451. (PMID: 33045929)
N Engl J Med. 2008 Sep 25;359(13):1317-29. (PMID: 18815396)
Circulation. 2017 Jan 31;135(5):440-448. (PMID: 27965285)
JAMA. 1995 Oct 4;274(13):1017-25. (PMID: 7563451)
Circ Res. 1989 Jul;65(1):83-94. (PMID: 2500270)
Eur Stroke J. 2021 Mar;6(1):I-LXII. (PMID: 33817340)
N Engl J Med. 2019 May 9;380(19):1795-1803. (PMID: 31067369)
Neurology. 2009 Mar 10;72(10):915-21. (PMID: 19273826)
Neuropsychiatr Dis Treat. 2022 May 11;18:1013-1026. (PMID: 35586365)
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3670-4. (PMID: 8170967)
JAMA Neurol. 2023 Jul 1;80(7):732-738. (PMID: 37252708)
JAMA Neurol. 2020 Oct 1;77(10):1203-1204. (PMID: 32687579)
J Biol Chem. 2000 Apr 7;275(14):10112-20. (PMID: 10744692)
N Engl J Med. 2024 Feb 22;390(8):701-711. (PMID: 38329148)
Pharmacotherapy. 2001 Feb;21(2):207-17. (PMID: 11213858)
Lancet. 2008 Oct 11;372(9646):1303-9. (PMID: 18790527)
Lancet. 2014 Nov 29;384(9958):1929-35. (PMID: 25106063)
Stroke. 2005 Mar;36(3):607-12. (PMID: 15692126)
N Engl J Med. 2018 Aug 16;379(7):611-622. (PMID: 29766770)
Lancet Neurol. 2022 Jun;21(6):520-527. (PMID: 35525251)
Stroke Vasc Neurol. 2024 Jan 29;:. (PMID: 38286484)
N Engl J Med. 2018 Apr 26;378(17):1573-1582. (PMID: 29694815)
Lancet. 2012 Oct 6;380(9849):1241-9. (PMID: 22932715)
Stroke. 2021 Jan;52(1):308-312. (PMID: 33272127)
Neurology. 2017 Jul 4;89(1):62-67. (PMID: 28576782)
Lancet. 1999 Aug 28;354(9180):716-22. (PMID: 10475182)
N Engl J Med. 2015 Mar 12;372(11):1019-30. (PMID: 25671798)
JAMA. 2020 Apr 7;323(13):1257-1265. (PMID: 32078683)
Stroke. 2010 Apr;41(4):707-11. (PMID: 20185783)
JAMA. 1999 Dec 1;282(21):2019-26. (PMID: 10591384)
Medicina (Kaunas). 2022 Aug 28;58(9):. (PMID: 36143846)
Lancet Neurol. 2017 Oct;16(10):781-788. (PMID: 28780236)
Eur Stroke J. 2023 Mar;8(1):8-54. (PMID: 37021186)
N Engl J Med. 2015 Mar 12;372(11):1009-18. (PMID: 25671797)
Lancet. 2012 Jun 23;379(9834):2352-63. (PMID: 22632908)
J Stroke. 2013 May;15(2):90-8. (PMID: 24324944)
CNS Drugs. 2016 Feb;30(2):101-8. (PMID: 26798040)
Acta Neurol Scand. 2020 Nov;142(5):475-479. (PMID: 32511749)
Stroke Vasc Neurol. 2023 Aug 1;:. (PMID: 37527920)
Neurology. 2022 Mar 22;98(12):e1292-e1301. (PMID: 35017305)
Int J Stroke. 2016 Jul;11(5):534-43. (PMID: 27048693)
Vascul Pharmacol. 2006 Jan;44(1):1-9. (PMID: 16275118)
Stroke. 2020 Dec;51(12):3681-3689. (PMID: 33023423)
Pan Afr Med J. 2015 May 19;21:37. (PMID: 26405473)
N Engl J Med. 2012 Mar 22;366(12):1099-107. (PMID: 22435369)
Lancet. 2023 Feb 25;401(10377):645-654. (PMID: 36774935)
Ann Neurol. 2021 Jul;90(1):1-3. (PMID: 33934380)
Stroke Vasc Neurol. 2023 Aug 28;:. (PMID: 37640500)
Lancet Neurol. 2008 Apr;7(4):299-309. (PMID: 18296121)
N Engl J Med. 1995 Dec 14;333(24):1581-7. (PMID: 7477192)
Stroke. 2022 Dec;53(12):3583-3593. (PMID: 36148657)
Br J Haematol. 2005 May;129(3):307-21. (PMID: 15842654)
Lancet Neurol. 2023 Feb;22(2):117-126. (PMID: 36549308)
Thromb Haemost. 1998 Jan;79(1):134-9. (PMID: 9459338)
Stroke. 2000 Apr;31(4):811-6. (PMID: 10753980)
Lancet Neurol. 2015 Apr;14(4):368-76. (PMID: 25726502)
Ther Adv Neurol Disord. 2021 Jan 12;14:1756286420986727. (PMID: 33488774)
Stroke. 2015 Mar;46(3):769-74. (PMID: 25677596)
Nature. 1989 Jun 29;339(6227):721-4. (PMID: 2500599)
Stroke Vasc Neurol. 2022 Feb;7(1):47-53. (PMID: 34429364)
Stroke. 2019 Aug;50(8):2156-2162. (PMID: 31318627)
Lancet. 2022 Jul 16;400(10347):161-169. (PMID: 35779553)
Int J Stroke. 2021 Apr;16(3):295-299. (PMID: 32631157)
Int J Stroke. 2019 Jul;14(5):483-490. (PMID: 30947642)
Stroke. 2021 Mar;52(3):1087-1090. (PMID: 33588597)
Lancet. 1998 Oct 17;352(9136):1245-51. (PMID: 9788453)
J Clin Neurosci. 2021 Sep;91:299-305. (PMID: 34373043)
Lancet Neurol. 2021 Oct;20(10):795-820. (PMID: 34487721)
Stroke. 2019 Dec;50(12):e344-e418. (PMID: 31662037)
Circulation. 1995 Nov 15;92(10):3032-40. (PMID: 7586274)
Stroke. 2021 Oct;52(10):e590-e593. (PMID: 34465202)

Keywords: alteplase; ischemic stroke; tenecteplase; thrombolysis

WGD229O42W (Tenecteplase)
0 (Fibrinolytic Agents)
EC 3.4.21.68 (Tissue Plasminogen Activator)

Date Created: 20240430 Date Completed: 20240507 Latest Revision: 20240618

20240618

PMC11179942

10.1161/JAHA.123.031692

38686848